HCPCS S9537: Home Hematopoietic Hormone Injection Therapy, Administrative Services
HCPCS Level II code S9537 designates per-diem administrative and professional pharmacy services for home-based hematopoietic hormone injection therapy, such as erythropoietin or colony-stimulating factors. The code captures care coordination, supplies, and equipment needed to support home injection regimens while the actual drug products and nursing visits are billed separately. Nationally, this code matters for payers and providers coordinating complex outpatient and home-based supportive care for patients requiring hematopoietic growth factors.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, guidance on how the code is used alongside separate drug and nursing line items, and discussion of common billing considerations. The publication also summarizes benchmarks and policy updates relevant to per-diem home therapy administrative codes, and outlines operational implications for pharmacy, care coordination, and home infusion programs.
Data not available in the input for specific associated taxonomies, ICD-10 diagnoses, and related codes.
Customize your policy alerts
Sign up for hcpcs S9537 policy alerts
Get alerted when payer policies referencing S9537 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code S9537 describes home therapy for hematopoietic hormone injection therapy (for example, erythropoietin, G-CSF, GM-CSF). The code covers administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment provided on a per diem basis. Drugs and nursing visits associated with the therapy are coded separately.
Service type: Home infusion and therapy administrative services
Typical site of service: Patient's home (home health/home infusion setting)